TickerFacts.

Adaptimmune Therapeutics PLC (ADAPY): Free Cash Flow

Operating cash flow minus capital expenditures for the same annual period and currency, computed by TickerFacts from the filed figures. A simple proxy, not a reported figure; a year without both inputs is left out.

Not updated since 2024-12-31. No annual report in US GAAP has been filed since. Companies that switch to IFRS reporting, as many foreign filers do, or stop filing are not updated here.

-$74.09M
Year ended 2024-12-31
$35.47M2014-06-30: $35.47M2015-06-30: -$34.75M2016-12-31: -$59.67M2017-12-31: -$78.96M2018-12-31: -$108.30M2019-12-31: -$114.10M2020-12-31: -$55.93M2021-12-31: $2.15M2022-12-31: -$171.26M2023-12-31: -$145.56M2024-12-31: -$74.09M-$74.09M
2014-06-30 Free Cash Flow (USD) 2024-12-31
Period endedFree Cash FlowChange YoYSource filing
2024-12-31-$74.09Mn/m2025-03-24, From 2024-01-01
2023-12-31-$145.56Mn/m2025-03-24, From 2023-01-01
2022-12-31-$171.26Mn/m2025-03-24, From 2022-01-01
2021-12-31$2.15Mn/m2024-03-06, From 2021-01-01
2020-12-31-$55.93Mn/m2023-03-06, From 2020-01-01
2019-12-31-$114.10Mn/m2022-03-14, From 2019-01-01
2018-12-31-$108.30Mn/m2021-02-25, From 2018-01-01
2017-12-31-$78.96Mn/m2019-02-27, From 2017-01-01
2016-12-31-$59.67Mn/a2019-02-27, From 2016-01-01
No annual figure between 2015-06-30 and 2016-12-31.
2015-06-30-$34.75Mn/m2018-03-15, From 2014-07-01
2014-06-30$35.47Mn/a2017-03-13, From 2013-07-01